Dr. Wei on Trial of Venetoclax Plus Chemotherapy in AML

Andrew Wei, MBBS, PhD
Published: Thursday, Mar 30, 2017



Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).

A phase I trial was conducted to answer the question of whether targeting BCL-2 would be effective in AML.

Venetoclax was combined with low-dose chemotherapy to see whether the combination would raise response rates in relapsed/refractory patients. The combination was very well tolerated, with few severe side effects being reported.
 


Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).

A phase I trial was conducted to answer the question of whether targeting BCL-2 would be effective in AML.

Venetoclax was combined with low-dose chemotherapy to see whether the combination would raise response rates in relapsed/refractory patients. The combination was very well tolerated, with few severe side effects being reported.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x